Chemotherapy for prostate cancer;Chemotherapie beim prostatakarzinom

Wiener Klinische Wochenschrift

Volumn 120, Issue 13-14, 2008, Pages 440-449

  Rauchenwald, Michael ^a   De Santis, Maria ^c   Fink, Eleonore ^d   Höltl, Wolfgang ^c   Kramer, Gero ^a   Marei, Isabella Carolina ^e   Neumann, Hans Jörg ^f   Reissigl, Andreas ^a   Schmeller, Nikolaus ^g   Stackl, Walter ^a   Hobisch, Alfred ^h   Krainer, Michael ^b  

^a Urologische Universitatsklinik   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d Abteilung für Urologie   (Austria)

^e DANUBE HOSPITAL   (Austria)

^f KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^g UNIVERSITY OF SALZBURG   (Austria)

^h Landeskrankenhaus Feldkirch   (Austria)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory; Palliative car; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE; HORMONE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ALOPECIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; NEUTROPENIA; ONCOLOGY; PALLIATIVE THERAPY; PATIENT CARE; PERIPHERAL EDEMA; PHYSICIAN; PROSTATE CANCER; SENSORY NEUROPATHY; STOMATITIS; UROLOGY;

EID: 51749113566     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1008-3     Document Type: Conference Paper

References (80)

1. Keine Autoren angegeben: SEER Stage Distribution by Race For Prostate Cancer, All Ages, Males, SEER 9 Registries for 1975-1979, 1985-1989, 1996-2003. SEER - Surveillance Epidemiology and End Results
2. C Vutuc T Waldhoer S Madersbacher M Micksche G Haidinger 2001 Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality Eur J Cancer Prev 10 5 425 428
3. Statistik Austria: Prostata. Gesundheitsstatistiken/Inzidenz von Krebserkrankungen 2001-2003. www.statistik.at/web_de/statistiken/gesundheit/ krebserkrankungen/prostata/index.html. Zuletzt aufgerufen am 26.10.2007
4. SS Chang MC Benson SC Campbell J Crook R Dreicer CP Evans 2005 Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma Cancer 103 1 11 21
5. HI Scher G Steineck WK Kelly 1995 Hormone-refractory (D3) prostate cancer: refining the concept Urology 46 2 142 148
6. Heidenreich A, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, et al (Update March 2007) Guidelines on Prostate Cancer. European Association of Urology
7. N Tsuchiya L Wang H Suzuki T Segawa H Fukuda S Narita 2006 Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer J Clin Oncol 24 13 1982 1989
8. S Kojima H Suzuki K Akakura M Shimbo T Ichikawa H Ito 2004 Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy J Urol 171 2 Pt 1 679 683
9. K Miller K Becker F Finke G Geiges B Gockel-Beining DK Hossfeld 2006 Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma Aktuelle Urol 37 3 201 204
10. CN Sternberg M Krainer WK Oh S Bracarda J Bellmunt H Ozen 2007 The medical management of prostate cancer: a multidisciplinary team approach BJU Int 99 1 22 27
11. A Yagoda D Petrylak 1993 Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 71 3 Suppl 1098 1109
12. PW Kantoff S Halabi M Conaway J Picus J Kirshner V Hars 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 8 2506 2513
13. IF Tannock D Osoba MR Stockler DS Ernst AJ Neville MJ Moore 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 6 1756 1764
14. RP Abratt D Brune MA Dimopoulos J Kliment J Breza FP Selvaggi 2004 Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer Ann Oncol 15 11 1613 1621
15. G Hudes L Einhorn E Ross A Balsham P Loehrer H Ramsey 1999 Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial J Clin Oncol 17 10 3160 3166
16. DM Savarese S Halabi V Hars WL Akerley ME Taplin PA Godley 2001 Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B J Clin Oncol 19 9 2509 2516
17. VJ Sinibaldi MA Carducci S Moore-Cooper M Laufer M Zahurak MA Eisenberger 2002 Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 5 1457 1465
18. M Sitka Copur P Ledakis J Lynch R Hauke S Tarantolo M Bolton 2001 Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer Semin Oncol 28 4 Suppl 15 16 21
19. M Krainer S Tomek K Elandt P Horak W Albrecht M Eisenmenger 2007 A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer J Urol 177 6 2141 2145
20. DP Petrylak CM Tangen MH Hussain PN Lara Jr JA Jones ME Taplin 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 1513 1520
21. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 1502 1512
22. F Calabro CN Sternberg 2007 Current indications for chemotherapy in prostate cancer patients Eur Urol 51 1 17 26
23. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD (2006) Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev (4): CD005247
24. AJ Armstrong E Garrett-Mayer YC Ou Yang MA Carducci I Tannock R de Wit 2007 Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 25 3965 3970
25. Oudard S, Banu E, Medioni J, Dionysopoulos D, Cojocarasu O, Banu A (2007) What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel? ASCO Annual Meeting 2007. Abstract #5149. http://tinyurl.com/yskqka. Zuletzt aufgerufen am 26.10.2007
26. J Bellmunt S Albiol J Albanell 2007 Intermittent chemotherapy in metastatic androgen-independent prostate cancer BJU Int 100 3 490 492
27. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether J, et al (2006) Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): initial results from ASCENT. ASCO Prostate Cancer Symposium 2006. Abstract #216. http://tinyurl.com/2wnue4. Zuletzt aufgerufen am 26.10.2007
28. TM Beer CW Ryan PM Venner DP Petrylak GS Chatta JD Ruether 2007 Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators J Clin Oncol 25 6 669 674
29. Miller K, Wulfing C, Lehmann J, Johannsen M, Heidenreich A, Hegele A, et al (2005) Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition. Preliminary results of a multicenter phase II study (AUO AP33/02). ASCO Annual Meeting 2005. Abstract #4613. http://tinyurl.com/34w5hc. Zuletzt aufgerufen am 26.10.2007
30. Nelius T, Klatte T, de Riese W, Filleur S (2007) Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol 2007; e-pub Jun 30; doi: 10.1007/s11255-007-9221-y
31. Armstrong AJ, Eisenberger MA, Garrett-Mayer ES, Ou Yang Y, Carducci MA, De Wit R, et al (2007) Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC). ASCO Annual Meeting 2007. Abstract #5009. http://tinyurl.com/2bl6v2. Zuletzt aufgerufen am 26.10.2007
32. DP Petrylak DP Ankerst CS Jiang CM Tangen MH Hussain PN Lara Jr 2006 Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 8 516 521
33. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick J, Joniau S, et al (2007) SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men. ECCO 2007. Abstract #1305
34. Luedecke G, Hauptmann A, Koehler E, Weidner W (2007) Optimized palliative care in hormone refractory prostate cancer (HRPC) patients in advanced age: Four years of uro-oncological experiences in ambulant docetaxel chemotherapy. Prostate Cancer Symposium 2007. Abstract #255. http://tinyurl.com/2kjcsw. Zuletzt aufgerufen am 26.10.2007
35. J Anderson H Van Poppel J Bellmunt K Miller JP Droz JM Fitzpatrick 2007 Chemotherapy for older patients with prostate cancer BJU Int 99 2 269 273
36. TM Beer W Berry EM Wersinger LB Bland 2003 Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years Clin Prostate Cancer 2 3 167 172
37. Chittoor SR, Berry WR, Loesch DM, Logie KW, Fleagle J, Mull S, et al (2005) Phase II study of low dose (weekly) docetaxel and estramustine in elderly males (age > 75 years) with hormone-refractory prostate cancer or patients age 18 to 74 years with an ECOG performance status of 2 or 3. ASCO Annual Meeting 2005. Abstract #4646. http://tinyurl.com/2j939v. Zuletzt aufgerufen am 26.10. 2007
38. Luedecke G, Hauptmann A, Koehler E, Weidner W (2007) Optimized palliative care in hormone refractory prostate cancer (HRPC) patients in advanced age by low dose Taxotere therapy and intermittent application. 22nd Annual EAU Congress 2007. Abstract #310. www.uroweb.org/publications/eau-abstracts-online/?AID= 14563. Zuletzt aufgerufen am 26.10.2007
39. L Repetto L Fratino RA Audisio A Venturino W Gianni M Vercelli 2002 Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study J Clin Oncol 20 2 494 502
40. A Heidenreich F Sommer CH Ohlmann AJ Schrader P Olbert J Goecke 2004 Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma Cancer 101 5 948 956
41. AT Porter AJ McEwan JE Powe R Reid DG McGowan H Lukka 1993 Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 5 805 813
42. F Saad DM Gleason R Murray S Tchekmedyian P Venner L Lacombe 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 19 1458 1468
43. Loidl W, Albrecht W, De Santis M, Höltl W, Kramer G, Stoiber F (2005) Leitlinien zur hämatologisch-supportiven Therapie bei urologischen Karzinomen. NÖGU - Nachrichten der Österr Gesellsch f Urol u Androl 2005 (32). www.uro.at/mm/mm003/Leitlinien_AUO.pdf. Zuletzt aufgerufen am 26.10.2007
44. J Crawford B Althaus J Armitage DW Blayney S Cataland DC Dale 2005 Myeloid growth factors clinical practice guidelines in oncology J Natl Compr Canc Netw 3 4 540 555
45. C Bokemeyer MS Aapro A Courdi J Foubert H Link A Osterborg 2004 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer Eur J Cancer 40 15 2201 2216
46. H Ludwig G Gastl 2004 Stellenwert von Erythropoietin in der Behandlung der Anämie bei Patienten mit malignen Erkrankungen - Therapieempfehlungen der Österreichischen Gesellschaft für Hämatologie und Onkologie/Ergebnisbericht von einem Expertenworkshop Newsletter der ÖGHO 1 9 12
47. Keine Autoren angegeben (1986) Cancer pain relief. World Health Organization, Genf
48. Keine Autoren angegeben (1990) Cancer pain relief and palliative care - report of a WHO expert committee. World Health Organization, Genf
49. Keine Autoren angegeben (1996) Cancer pain relief: with a guide to opioid availability. WHO, Genf
50. AS Kibel E Rosenbaum MW Kattan J Picus R Dreicer EA Klein 2007 Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study J Urol 177 5 1777 1781
51. J Pendleton LL Pisters K Nakamura S Anai CJ Rosser 2007 Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? Urol Oncol 25 1 11 18
52. CN Sternberg 1999 Hormonal therapy and radiation therapy in the treatment of locally advanced prostate cancer Mol Urol 3 3 227 230
53. PG Febbo JP Richie DJ George M Loda J Manola S Shankar 2005 Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer Clin Cancer Res 11 14 5233 5240
54. M Garzotto A Myrthue CS Higano TM Beer 2006 Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer Urol Oncol 24 3 254 259
55. S Goodin P Medina T Capanna WJ Shih S Abraham J Winnie 2005 Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer J Clin Oncol 23 15 3352 3357
56. A Hussain N Dawson P Amin C Engstrom B Dorsey E Siegel 2005 Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer J Clin Oncol 23 12 2789 2796
57. NM Hahn S Marsh W Fisher R Langdon R Zon M Browning 2006 Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis Clin Cancer Res 12 20 Pt 1 6094 6099
58. R Petrioli L Paolelli E Francini A Manganelli F Salvestrini G Francini 2007 Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer Urology 69 1 142 146
59. JM Ferrero E Chamorey S Oudard S Dides G Lesbats G Cavaglione 2006 Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer Cancer 107 4 738 745
60. Lan F, Ballard H, Chen A, Leung R, Chachoua A, Taneja S, et al (2007) Phase I/II study of sequential-intermittent docetaxel (D) and imatinib (Im) in hormone refractory prostate caner (HRPC) (NYU 04-47). ASCO Annual Meeting 2007. Abstract #15613. http://tinyurl.com/2b29zv. Zuletzt aufgerufen am 26.10.2007
61. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, et al (2006) Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). ASCO Annual Meeting 2006. Abstract #4562. http://tinyurl.com/2arws6. Zuletzt aufgerufen am 26.10. 2007
62. Ning YM, Arlen P, Gulley L, Latham L, Jones E, Chen C, et al (2007) A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). ASCO Annual Meeting 2007. Abstract #5114. http://tinyurl.com/27fost. Zuletzt aufgerufen am 26.10.2007
63. AM Lin CJ Ryan EJ Small 2007 Intermittent chemotherapy for metastatic hormone refractory prostate cancer Crit Rev Oncol Hematol 61 3 243 254
64. AK Thomas-Kaskel R Zeiser R Jochim C Robbel W Schultze-Seemann CF Waller 2006 Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival Int J Cancer 119 10 2428 2434
65. PA Lodge LA Jones RA Bader GP Murphy ML Salgaller 2000 Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial Cancer Res 60 4 829 833
66. PA Burch GA Croghan DA Gastineau LA Jones JS Kaur JW Kylstra 2004 Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial Prostate 60 3 197 204
67. EJ Small P Fratesi DM Reese G Strang R Laus MV Peshwa 2000 Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 23 3894 3903
68. EJ Small PF Schellhammer CS Higano CH Redfern JJ Nemunaitis FH Valone 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 3089 3094
69. G Beinart BI Rini V Weinberg EJ Small 2005 Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer Clin Prostate Cancer 4 1 55 60
70. Morris MJ, Milowsky MI, Pandit-Taskar N, Divgi C, David KA, Rozario CP, et al (2006) Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). ASCO Annual Meeting 2006. Abstract #4613. http://tinyurl.com/ 32nkm3. Zuletzt aufgerufen am 26.10.2007
71. A Heiser D Coleman J Dannull D Yancey MA Maurice CD Lallas 2002 Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors J Clin Invest 109 3 409 417
72. M Mercader BK Bodner MT Moser PS Kwon ES Park RG Manecke 2001 T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci USA 98 25 14565 14570
73. Gerritsen W, Van den Eertwegh AJ, De Gruijl TD, Giaccone G, Scheper J, Sacks N, et al (2007) A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipiluminab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Prostate Cancer Symposium 2007. Abstract #262. http://tinyurl.com/2pckxe. Zuletzt aufgerufen am 26.10.2007
74. Fong L, Kavanagh B, Hou Y, O'Brien S, Valiente J, Weinberg V, et al (2007) Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells. ASCO Annual Meeting 2007. Abstract #3001. http://tinyurl.com/2tfzav. Zuletzt aufgerufen am 26.10.2007
75. KW Beekman MT Fleming HI Scher SF Slovin NM Ishill G Heller 2005 Second-line chemotherapy for prostate cancer: patient characteristics and survival Clin Prostate Cancer 4 2 86 90
76. R Petrioli A Pascucci E Francini S Marsili A Sciandivasci G De Rubertis 2007 Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel BJU Int 100 4 775 779
77. R Petrioli D Pozzessere S Messinese M Sabatino T Di Palma S Marsili 2003 Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy Oncology 64 4 300 305
78. Sternberg CN, Petrylak D, Witjes F, Ferrero J, Eymard J, Falcon S, et al (2007) Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. ASCO Annual Meeting 2007. Abstract #5019. http://tinyurl.com/25 dqwr. Zuletzt aufgerufen am 27.10.2007
79. JE Rosenberg VK Weinberg WK Kelly D Michaelson MH Hussain G Wilding 2007 Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 3 556 563
80. DR Berthold CN Sternberg IF Tannock 2005 Management of advanced prostate cancer after first-line chemotherapy J Clin Oncol 23 32 8247 8252